
-
Citius Pharmaceuticals NasdaqCM:CTXR Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Location: 11 Commerce Drive, Cranford, NJ, 07016, United States | Website: https://citiuspharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.09M
Cash
26.41K
Avg Qtr Burn
-5.886M
Short % of Float
6.33%
Insider Ownership
4.79%
Institutional Own.
6.24%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYMPHIR (Denileukin Diftitox-cxdl, E7777) Details T-cell lymphoma | Approved Quarterly sales | |
Mino-Lok Details Catheter related blood stream infections | Phase 3 Update | |
Halo-Lido (CITI-102) Details Hemorrhoids | Phase 2b Update | |
Pembrolizumab (KEYTRUDA®) + LYMPHIR™ Details Solid tumor/s | Phase 1 Data readout |